Thermo Fisher’s first quarter results received a negative market reaction, despite topping Wall Street’s revenue expectations and delivering non-GAAP earnings ahead of consensus. Management attributed the quarter’s performance to strong bioproduction and clinical research businesses, while acknowledging ongoing headwinds in academic, government, and diagnostics markets, particularly in the U.S. and China. CEO Marc Casper described end market performance as “very predictable,” emphasizing that the quarter played out as anticipated. Casper also cited the successful integration of the Clario acquisition and highlighted ongoing productivity initiatives intended to offset inflationary pressures and unfavorable product mix.
Is now the time to buy TMO? Find out in our full research report (it’s free for active Edge members).
Thermo Fisher (TMO) Q1 CY2026 Highlights:
- Revenue: $11.01 billion vs analyst estimates of $10.84 billion (6.2% year-on-year growth, 1.5% beat)
- Adjusted EPS: $5.44 vs analyst estimates of $5.24 (3.8% beat)
- Adjusted EBITDA: $2.71 billion vs analyst estimates of $2.63 billion (24.6% margin, 2.9% beat)
- Operating Margin: 16.9%, in line with the same quarter last year
- Organic Revenue rose 1% year on year (miss)
- Market Capitalization: $173.3 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Thermo Fisher’s Q1 Earnings Call
- Michael Ryskin (Bank of America) asked about the confidence in achieving full-year guidance given the ramp needed later in the year. CEO Marc Casper responded that growth progression is largely due to calendar effects and phasing, not an assumed change in end market conditions.
- Tycho Peterson (Jefferies) requested updates on clinical research momentum and Clario’s early impact. Casper described strong customer engagement and improving biotech funding, noting positive initial feedback on Clario integration.
- Jack Meehan (Nephron Research) inquired about AI’s influence on customer spending and upcoming offerings leveraging Clario data. Casper emphasized AI’s potential to accelerate drug development and said Thermo Fisher is well positioned to benefit from industry adoption.
- Daniel Arias (Stifel) questioned whether any macro risks had been “retired” after the quarter. Casper stated that Q1 played out as expected, reducing risk, but inflation remains a variable the company is actively working to offset.
- Matthew Larew (William Blair) probed how AI adoption could influence instrument development and usage. Casper explained demand is shifting toward automation and connectivity, with R&D focused on enabling large-scale data generation and integration.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will monitor (1) the pace of Clario integration and its contribution to clinical research growth, (2) stabilization or recovery in academic and government spending, particularly in the U.S. and China, and (3) the ongoing impact of inflation and tariffs on margins. Additionally, we will watch for continued adoption of AI-enabled products and the success of new product launches in driving top-line growth.
Thermo Fisher currently trades at $463.98, down from $513.98 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
